Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine

Yasunori Watanabe, Luiza Mendonça, Elizabeth R. Allen, Andrew Howe, Mercede Lee, Joel D. Allen, Himanshi Chawla, David Pulido, Francesca Donnellan, Hannah Davies, Marta Ulaszewska, Sandra Belij-Rammerstorfer, Susan Morris, Anna Sophia Krebs, Wanwisa Dejnirattisai, Juthathip Mongkolsapaya, Piyada Supasa, Gavin R. Screaton, Catherine M. Green, Teresa LambePeijun Zhang, Sarah C. Gilbert, Max Crispin

Research output: Contribution to journalArticlepeer-review

89 Scopus citations


Vaccine development against the SARS-CoV-2 virus focuses on the principal target of the neutralizing immune response, the spike (S) glycoprotein. Adenovirus-vectored vaccines offer an effective platform for the delivery of viral antigen, but it is important for the generation of neutralizing antibodies that they produce appropriately processed and assembled viral antigen that mimics that observed on the SARS-CoV-2 virus. Here, we describe the structure, conformation, and glycosylation of the S protein derived from the adenovirus-vectored ChAdOx1 nCoV-19/AZD1222 vaccine. We demonstrate native-like post-translational processing and assembly, and reveal the expression of S proteins on the surface of cells adopting the trimeric prefusion conformation. The data presented here confirm the use of ChAdOx1 adenovirus vectors as a leading platform technology for SARS-CoV-2 vaccines.

Original languageEnglish (US)
Pages (from-to)594-602
Number of pages9
JournalACS Central Science
Issue number4
StatePublished - Apr 28 2021
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2021 American Chemical Society. All rights reserved.


Dive into the research topics of 'Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine'. Together they form a unique fingerprint.

Cite this